Federal Regulations For Prescribing Scheduled Controlled Substances



Similar documents
Information for Pharmacists

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

Ohio Legislative Service Commission

What Every Practitioner Needs to Know About Controlled Substance Prescribing

Using Buprenorphine in an Opioid Treatment Program

MEDICAL ASSISTANCE BULLETIN

Exceptions to the Rule: A Pharmacy Law Presentation. Objectives DISCLAIMER 10/16/2015

Schedule II Drug Program Law Component

Schedule II Drug Program Law Component

MEDICAL ASSISTANCE BULLETIN

Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain

Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998

KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE

MEDICAL POLICY Treatment of Opioid Dependence

02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION

Controlled II Substance Rules & Regulations. Controlled II Substance Rules & Regulations

Physician Information. Answers to Frequently Asked Questions

How To Treat Anorexic Addiction With Medication Assisted Treatment

Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction

RULES OF THE TENNESSEE BOARD OF NURSING CHAPTER ADVANCED PRACTICE NURSES AND CERTIFICATES OF FITNESS TO PRESCRIBE TABLE OF CONTENTS

SUBOXONE /VIVITROL WEBINAR. Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12

Pain Management Regulations Affect More Than Pain Management Specialists January Of counsel to

ADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN

Appendices to Interim Report on the Baltimore Buprenorphine Initiative. Managed Care Organization Information Pages

Narcotic Treatment Programs

EPCS FREQUENTLY ASKED QUESTIONS FOR ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES. Revised: January 2016

POLICY AND PROCEDURES FOR PROVIDING NARCOTIC ADDICTION TREATMENT TO PREGNANT OPIOID DEPENDENT INMATES INCARCERATED IN THE COUNTY JAIL

National Alliance of Methadone Advocates

Prior Authorization Guideline

Various therapies are used in the

Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment of Pain

ADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN

ARKANSAS DEPARTMENT OF HEALTH

Frequently asked questions

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES

ARCHIVED BULLETIN. Product No L SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E

ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS

MISSISSIPPI LEGISLATURE REGULAR SESSION 2016

DEA REGISTRATION FEES FACT SHEET

Drug Diversion. Controlled Substance Prescribing and Diversion

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

MEDICAID DRUG SPENDING ON ANTI- ADDICTION MEDICATION AND OPIOID ADDICTION REFRESHER

Louisiana Administrative Code. Title 46 Professional and Occupational Standards. Part LIII: Pharmacists

The Determinations Report: A Report On the Physician Waiver Program Established by the. Drug Addiction Treatment Act of 2000 ( DATA )

TREATMENT MODALITIES. May, 2013

Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:

Program Assistance Letter

AMERICAN PSYCHOLOGICAL ASSOCIATION

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

American Society of Addiction Medicine

FREQUENTLY ASKED QUESTIONS

Practice Protocol. Buprenorphine Guidance Protocol

02- DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION. Chapter 8 REGULATIONS RELATING TO ADVANCED PRACTICE REGISTERED NURSING

Opioid Treatment Services, Office-Based Opioid Treatment

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-8 ADVANCED PRACTICE NURSES: COLLABORATIVE PRACTICE TABLE OF CONTENTS

Use of Pharmacotherapies by Substance Abuse Treatment Facilities

MAD-MR: SPECIALTY SERVICES EFF: MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION INDEX

The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section

NH Laws / Rules Regarding Limited Retail Drug Distributors

This module will assist participants to:

How To Get A Prescription In Rhode Island

Prescribers required to check PDMP before first prescription for Controled Substances for new patient.

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS

INSTRUCTIONS AND PROTOCOLS FOR THE IMPLEMENTATION OF MEDICATION-ASSISTED TREATMENT FOR OPIOID/OPIATE DEPENDENCE

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff

MEDICAL ASSISTANCE BULLETIN

Guidelines for Use of Controlled Substances for the Treatment of Pain

SCOPE of Pain: Safe and Competent Opioid Prescribing Education

Substance Use: Addressing Addiction and Emerging Issues

Office-based Treatment of Opioid Dependence with Buprenorphine

RE: Medication Assisted Treatment for Opioid Use Disorders RIN 0930-AA22

Practitioner s Manual

Web-Based Resources. Locating Treatment

PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA

Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

REVIEW OF FEDERAL LAW FOR PHARMACY TECHNICIANS DR. SULLIVAN S MONOGRAPH

MQAC Rules for the Management of Chronic Non-Cancer Pain

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Arkansas Emergency Department Opioid Prescribing Guidelines

Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management

Statement of the Federation of State Medical Boards of the United States

FREQUENTLY ASKED QUESTIONS FOR ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES

Prescriber Behavior, Pain Treatment and Addiction Treatment

ENROLLED SENATE BILL No. 92

Federal Response to Opioid Abuse Epidemic

House Study Bill Introduced

MSD Guidelines for the Use of Controlled Substances for the Treatment of Pain

Frequently Asked Questions (FAQs) Treatment Authorization Request (TAR) Restriction on Antipsychotic Medications for the 0-17 Population

MAT Disclosures & Consents 1 of 6. Authorization & Disclosure

FREQUENTLY ASKED QUESTIONS FOR ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation

For a Healthier America: Reducing Prescription Drug Misuse and Abuse

CHAPTER Section 34 of P.L.1970, c.226 (C.24:21-34) is amended to read as follows:

ACTION ITEM COMPLETED TAB 44

Medication Assisted Treatment

Transcription:

Federal Regulations For Prescribing Scheduled Controlled Substances HEIT TEMPLATE.PPT 1

Central Principle of Balance With the Use of Controlled Substances Dual imperative of government Establish a system of controls to prevent Abuse Trafficking Diversion HEIT TEMPLATE.PPT 2 A Guide to Evaluation Achieving Balance in Federal & State Pain Policy Pain and Policy Studies Group University of Wisconsin Comprehensive Cancer Center July 2000

Central Principle of Balance With the Use of Controlled Substances Must ensure availability of controlled substances (CSs) for medical and scientific purposes Should be accessible to all patients who need them, including for the relief of pain HEIT TEMPLATE.PPT 3 A Guide to Evaluation Achieving Balance in Federal & State Pain Policy Pain and Policy Studies Group University of Wisconsin Comprehensive Cancer Center July 2000

The Tenets of Lawful Prescribing of CSs 21 CFR 1306.04 A lawful prescription for a CS Each separate prescription is issued for a legitimate medical purpose By an individual practitioner acting in the usual course of professional practice HEIT TEMPLATE.PPT 4

Scheduling of Controlled Substances Schedule I - Cannot be prescribed Schedule II - High potential for abuse Schedule III - Less abuse potential than Schedule II Schedule IV - Low abuse potential relative to Schedule III Schedule V - Low abuse potential relative to Schedule IV HEIT TEMPLATE.PPT 5 US Department of Justice, Drug Enforcement Administration. The Controlled Substances Act. In: Drugs of Abuse; 2005. Available at: http://www.usdoj.gov/dea/pubs/abuse/1-csa.htm#formal. Accessed October 1, 2009.

Federal vs. State Regulations Healthcare professionals must comply with both federal and state laws and regulations that govern prescribing scheduled CSs. Model Policy for the Use of Controlled Substances for the Treatment of Pain. Policy Statement: Federation of State Medical Boards of the United States, Inc; 2004 When federal laws or regulations differ from state laws or regulations, the more stringent rule applies. HEIT TEMPLATE.PPT 6

Federal Regulations HEIT TEMPLATE.PPT 7 Length of time a Schedule II CS prescription is valid Federal Regulations No limit State specific Virginia» Six-month limitation What is the length of time a Schedule II CS prescription is valid in your state?

Amount or duration of a Schedule II CS that can be prescribed at one time Federal Regulations No limit State specific Virginia No limit What is the amount or duration of a Schedule II CS that can be prescribed at one time in your state? HEIT TEMPLATE.PPT 8

A practitioner may prescribe methadone or any other narcotic to a narcotic addict for analgesic purposes. HEIT TEMPLATE.PPT 9 Drug Enforcement Administration Pharmacist s Manual April, 2004, p. 54

The Controlled Substances Act and Drug Enforcement Administration regulations contain no specific limits on the number of days worth of a Schedule II controlled substance that a physician may authorize per prescription. HEIT TEMPLATE.PPT 10 Drug Enforcement Administration Federal Register August 26, 2005, p. 50409

Requirements of CS prescription 21 CFR 1306.11 Prescriptions for Schedule II CSs must be written, with some exceptions 21 CFR 1306.21 Prescriptions for Schedule II-V CSs may be written, faxed, or orally transmitted HEIT TEMPLATE.PPT 11

21 CFR 1306.05 Prescriptions for CSs must be dated as of, and signed on, the day when issued Must never post date a prescription Must include full name and address of patient, drug name, dosage form, strength, quantity, and directions for use Must include the name, address, registration number of practitioner Must be written with ink, indelible pencil, or typewriter and manually signed by the practitioner HEIT TEMPLATE.PPT 12.

Refills of a prescription 21 CFR 1306.12 Prescriptions for Schedule II CSs can not be refilled 21 CFR 1306.22 Prescriptions for Schedule III-IV CSs can not be dispensed after 6 months from date of issue, or refilled more than 5 times Rules for refilling Schedule V CSs are not established by federal law, and the authorized number of refills depends on the professional judgment of the prescriber and the pharmacist HEIT TEMPLATE.PPT 13

Federal Regulations [cont d] Partial filling of a Schedule II prescription 21 CFR 1306.13 A pharmacist can partially fill a prescription for a Schedule II CS if: Unable to supply the full quantity of a written or emergency oral prescription Notates the quantity supplied on the prescription face Fills remaining portion of prescription within 72 hours A new prescription is needed if the time goes beyond 72 hrs Pharmacist must notify the prescribing practitioner if unable to supply remaining portion of the prescription HEIT TEMPLATE.PPT 14

Federal Regulations [cont d] Partial filling of a Schedule II prescription 21 CFR 1306.13 A patient with a terminal illness or in a long term care facility (LTCF) may have a prescription filled in partial quantities Pharmacist must record on the prescription whether the patient is terminally ill or a LTCF patient The prescription is valid for a period not to exceed 60 days from the date of issuance unless sooner terminated by the discontinuation of the medicine HEIT TEMPLATE.PPT 15

HEIT TEMPLATE.PPT 16 Facsimile of a Schedule II prescription may serve as the original written prescription in the following situations Patient is a resident of LTCF 21 CRF 1306.11 Prescription faxed to dispensing pharmacy Patient enrolled in a hospice program certified/paid for by Medicare under Title XVIII or licensed by the state Prescription faxed to dispensing pharmacy Note on script: i.e. Hospice patient For compounding for direct administration by parenteral, I.V., I.M., SQ, or intraspinal infusion

21CFR 1306.04(b) A prescription may not be issued in order for an individual practitioner to obtain CSs for supplying the individual practitioner for the purpose of general dispensing to patients. All prescriptions must be written for a specific patient HEIT TEMPLATE.PPT 17

21 CFR 1306.07 May administer, prescribe or dispense a Schedule II CS to a person with intractable pain, in which no relief or cure is possible or none has been found after a reasonable effort This language has served as the basis to define intractable pain in state law. HEIT TEMPLATE.PPT 18

21 CFR 1306.07 To administer or dispense directly (but not prescribe) narcotic drugs to a narcotic-dependent person for detoxification or maintenance treatment, a physician MUST have a separate registration with the DEA as an opioid treatment program (OTP). HEIT TEMPLATE.PPT 19

May treat acute/chronic pain with a Schedule II CS in a recovering narcotic-addicted patient Federal law or regulations do not prohibit the prescribing, dispensing or administering of a narcotic medication to a narcotic addicted patient for the purpose of alleviating pain if such prescribing is medically appropriate within standards set by the medical community One must keep good records to document the physician is treating a pain syndrome and not the disease of narcotic addiction HEIT TEMPLATE.PPT 20

21 CFR 1306.07 DEA does not impose any limitations on a physician or authorized hospital staff to administer or dispense (but not prescribe) narcotic drugs in a hospital to maintain or detoxify a person as an incidental adjunct to medical or surgical treatment of conditions other than addiction. HEIT TEMPLATE.PPT 21

21 CFR 1306.12(a) Refilling of Schedule II CSs is prohibited, requiring that a new prescription be issued for each quantity of the substance 21 CFR 1306.14(e) A pharmacist can not fill a prescription issued as one in a series of multiple prescriptions prior to the date written by the prescribing physician HEIT TEMPLATE.PPT 22 DEA s Office of Diversion Control website, www.deadiversion.usdoj.gov/ under Federal Register Notices>Rules 2007.

Interpretation of CFR 1306.12. Issuance of multiple prescriptions for Schedule II CSs DEA s regulations allow practitioners to provide individual patients with multiple prescriptions for a specific Schedule II CS, written on the same date, to be filled sequentially. The combined effect of such sequential multiple prescriptions is that it allows a patient to receive over time up to a 90-day supply of that CS. HEIT TEMPLATE.PPT 23 DEA s Office of Diversion Control website, www.deadiversion.usdoj.gov/ under Federal Register Notices>Rules 2007.

21 CFR 1306.12 Sequential prescriptions up to a 90-day supply of a Schedule II CS are permitted Example: Writing three prescriptions to be dispensed every 30 days by the pharmacist (all prescriptions have the same date of issuance) Write one prescription for one-third of the total quantity of CS to be prescribed Write a second prescription for one third of the total quantity of CS to be prescribed Write DO NOT FILL UNTIL / / on the second prescription, with the date 30 days after the first prescription date of issue Write a third prescription for one third of the total quantity of CS to be prescribed Write DO NOT FILL UNTIL / / on the third prescription, with the date 60 days after the first prescription date of issue HEIT TEMPLATE.PPT 24

John Doe M.D. 83 Arlington Blvd. Suite 532 Date: 10/01/10 Fairfax, VA 22031 Reg. No.: Patient s name: Address: Drug: Disp: # # (write out quantity) Sig: Signature of doctor: HEIT TEMPLATE.PPT 25

John Doe M.D. 83 Arlington Blvd. Suite 532 Date: 10/01/10 Fairfax, VA 22031 Reg. No.: Patient s name: Address: Drug: Disp: # # (write out quantity) Do Not Fill Until: Sig: 10/31/10 Signature of doctor: HEIT TEMPLATE.PPT 26

HEIT TEMPLATE.PPT 27 Drug Addiction Treatment Act of 2000 Office Based Opioid Treatment (OBOT) Buprenorphine with or without naloxone Prescribed by certified and specially trained physicians Has received a waiver from the requirement to register as an NTP from the Center for Substance Abuse Treatment (CSAT) of the Substance Abuse and Mental Health Services Administration (SAMHSA)

The Office of National Drug Control Policy Reauthorization Act of 2006 (P.L. 109-469, ONDCPRA) Modified restriction on the number of patients (30) a physician authorized under the Drug Addiction Treatment Act of 2000 (DATA 2000) can treat with buprenorphine with or without naloxone Under, ONDCPRA, physicians who meet the following criteria may notify the Secretary of Health and Human Services (HHS) of their need and intent to treat up to 100 patients at any one time HEIT TEMPLATE.PPT 28

Criteria for the physician Must currently be qualified under DATA 2000 At least one year must have elapsed since the physician submitted the initial notification for authorization Must certify his/her capacity to refer patients for appropriate counseling and other ancillary services Must certify that that the total number of patients at any one time will not exceed the applicable number http://buprenorphine.samhsa.gov/faq.html HEIT TEMPLATE.PPT 29

Can One Use Suboxone or Subutex for Analgesia? The off-label use of the sublingual formulations of buprenorphine (Suboxone /Subutex ) for the treatment of pain is not prohibited under DEA requirements. One does not need a wavier from CSAT but a valid license to prescribe a Schedule III CS HEIT TEMPLATE.PPT 30 Heit HA, Covington E, Good PA (Former Chief Liaison and Policy Section Office of Diversion Control): Dear DEA. Pain Medicine, 2004, Vol.5, No. 3: 303-08

21 CFR 1306.07 Narcotic-dependent patient Can administer (not prescribe) a narcotic drug to relieve acute withdrawal symptoms while arranging for a referral to an opioid treatment program (OTP) In or out patient One day s medication at a time Can be done for 3 days Can not be renewed or extended HEIT TEMPLATE.PPT 31

Emergency situation 21 CFR 1306.11 A pharmacist may dispense a Schedule II CS after receiving an oral authorization if: Quantity is limited to the emergency period only! Prescription shall be reduced to writing with all the required information except the signature of the practitioner The pharmacist makes a reasonable attempt to make sure the oral authorization came from a registered practitioner HEIT TEMPLATE.PPT 32

Emergency situation [cont d] 21 CFR 1306.11 A pharmacist MUST receive the written prescription within 7 days from an oral authorization The prescription should include: A Notation: Authorization for Emergency Dispensing Date of oral authorization If the information is not received within 7 days, the pharmacist is required to report this missing information to the DEA. HEIT TEMPLATE.PPT 33

Emergency situation [cont d] 21 CFR 290.10 Immediate administration of the CS is necessary for proper treatment No appropriate alternatives are available, including drugs in lower schedules or noncontrolled drugs Not reasonably possible for practitioner to provide a written prescription before dispensing HEIT TEMPLATE.PPT 34

Electronic Prescriptions for Controlled Substances 21 CFR 75(61).16236 Effective June 1, 2010 the CFR was revised to: Provide practitioners with the option of writing prescriptions for CSs electronically Addition to, not a replacement of, existing rules Permit pharmacies to receive, dispense, and archive these electronic prescriptions Provide pharmacies, hospitals, and practitioners with the ability to use modern technology for CS prescriptions while maintaining the closed system of controls on CSs HEIT TEMPLATE.PPT 35

HEIT TEMPLATE.PPT 36 Federal Regulations [cont d] Electronic Prescriptions 21 CFR 1306.08 A practitioner may sign and transmit e-prescriptions if all of the following requirements are met: Must comply with all other requirements for issuing CS prescriptions Must use an application that meets specific requirements (in Part 1311) Must comply with requirements for electronic orders and prescriptions (in Part 1311)

HEIT TEMPLATE.PPT 37 Federal Regulations [cont d] Electronic Prescriptions 21 CFR 1311.102 Practitioner responsibilities Rapid reporting of identified breaches Same responsibilities when issuing e-prescriptions for CSs as when issuing a paper or oral prescription Including issuing prescriptions only for a legitimate medical purpose and in the usual course of professional practice The prescription must conform in all essential respects to the law and regulation

Amendable Errors Changes a pharmacist can make to a prescription for a CS May add or change patient s address upon verification May change or add dosage form, drug strength, quantity, direction for use, or issue date Only after consultation with and agreement of the prescribing practitioner Such changes are noted on the prescription and medical records In compliance with state/local laws, regulations, or policies http://www.deadiversion.usdoj.gov/faq/general.htm#x_change HEIT TEMPLATE.PPT 38

Non-Amendable Errors Changes a pharmacist can not make to a prescription for a CS May never change the patient s name May never change the CS prescribed - except for generic substitution permitted by state law May never change the prescriber's signature http://www.deadiversion.usdoj.gov/faq/general.htm#rx_change HEIT TEMPLATE.PPT 39

Differentiating Between a Legitimate and an Appropriate Prescription Legitimate Doctor patient relationship Diagnosis for which the medication might be prescribed for reasonable therapeutic trial Practitioner lawfully able to prescribe the agent within the usual and customary practice Appropriate All of the above plus Careful assessment of risk (i.e. substance use disorder etc) HEIT TEMPLATE.PPT 40 Douglas L. Gourlay MD, MSc, FRCPC, FASAM

Federal Regulations For additional information about controlled substances diversion and its prevention www.deadiversion.usdoj.gov./ A complete copy of these slides are available on the following web sites 's (ASAM) American Academy of Pain Medicine (AAPM) http://www.painmed.org/clinical_info/index.html University of Wisconsin Pain & Policy Studies Group HEIT TEMPLATE.PPT 41 http://www.painpolicy.wisc.edu/

Conclusion: Healthcare practitioners can prescribe scheduled controlled substances approved by the FDA consistent with state and federal regulations to give their patients the best quality of life possible given the reality of their medical condition. HEIT TEMPLATE.PPT 42